U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H19F2N5O2
Molecular Weight 399.394
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIMODIVIR

SMILES

OC(=O)[C@H]1C2CCC(CC2)[C@@H]1NC3=C(F)C=NC(=N3)C4=CNC5=C4C=C(F)C=N5

InChI

InChIKey=JGPXDNKSIXAZEQ-SBBZOCNPSA-N
InChI=1S/C20H19F2N5O2/c21-11-5-12-13(7-24-17(12)23-6-11)18-25-8-14(22)19(27-18)26-16-10-3-1-9(2-4-10)15(16)20(28)29/h5-10,15-16H,1-4H2,(H,23,24)(H,28,29)(H,25,26,27)/t9?,10?,15-,16-/m0/s1

HIDE SMILES / InChI
Molecular Formula C20H19F2N5O2
Molecular Weight 399.394
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

JNJ-872 is an inhibitor of influenza virus replication that offers a potential for the treatment of pandemic and seasonal influenza.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Polymerase basic protein 2
3
Target ID: P03427
Gene ID: NA
Gene Symbol: PB2
Target Organism: Influenza A virus (strain A/Wilson-Smith/1933 H1N1) (Influenza A virus|||(strain A/WS/1933 H1N1))
Interacts
323
Inhibitor
8504
 0.32 nM [EC50]
Inhibitor
8504
 1.6 µM [Ki]
PubMed

PubMed

TitleDatePubMed
Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial.
2019-03-15
Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.
2018-11
Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
2018
Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza.
2017-02-09
JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses.
2016-09
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
2014-08-14
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:34:53 GMT 2025
Edited
by admin
on Mon Mar 31 18:34:53 GMT 2025
Record UNII
DFC121MXC3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIMODIVIR
INN   WHO-DD  
INN  
Official Name English
pimodivir [INN]
Preferred Name English
JNJ-63623872-ZCD
Code English
JNJ872
Code English
VX-787 ANHYDROUS BASE
Common Name English
JNJ-63623872
Code English
(2S,3S)-3-((5-FLUORO-2-(5-FLUORO-1H-PYRROLO(2,3-B)PYRIDIN- 3-YL)PYRIMIDIN-4-YL)AMINO)BICYCLO(2.2.2)OCTANE-2-CARBOXYLIC ACID
Systematic Name English
Pimodivir [WHO-DD]
Common Name English
VX-787
Code English
JNJ-872
Code English
BICYCLO(2.2.2)OCTANE-2-CARBOXYLIC ACID, 3-((5-FLUORO-2-(5-FLUORO-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)-4-PYRIMIDINYL)AMINO)-, (2S,3S)-
Systematic Name English
JNJ63623872
Code English
(2S,3S)-3-(5-FLUORO-2-(5-FLUORO-1H-PYRROLO(2,3-B)PYRIDIN-3-YL)PYRIMIDIN-4-YLAMINO)BICYCLO(2.2.2)OCTANE-2-CARBOXYLIC ACID
Systematic Name English
PIMODIVIR [USAN]
Common Name English
Code System Code Type Description
FDA UNII
DFC121MXC3
Created by admin on Mon Mar 31 18:34:53 GMT 2025 , Edited by admin on Mon Mar 31 18:34:53 GMT 2025
PRIMARY
NCI_THESAURUS
C158086
Created by admin on Mon Mar 31 18:34:53 GMT 2025 , Edited by admin on Mon Mar 31 18:34:53 GMT 2025
PRIMARY
SMS_ID
100000174647
Created by admin on Mon Mar 31 18:34:53 GMT 2025 , Edited by admin on Mon Mar 31 18:34:53 GMT 2025
PRIMARY
WIKIPEDIA
Pimodivir
Created by admin on Mon Mar 31 18:34:53 GMT 2025 , Edited by admin on Mon Mar 31 18:34:53 GMT 2025
PRIMARY
NCI_THESAURUS
C170320
Created by admin on Mon Mar 31 18:34:53 GMT 2025 , Edited by admin on Mon Mar 31 18:34:53 GMT 2025
ALTERNATIVE
INN
10321
Created by admin on Mon Mar 31 18:34:53 GMT 2025 , Edited by admin on Mon Mar 31 18:34:53 GMT 2025
PRIMARY
PUBCHEM
67286591
Created by admin on Mon Mar 31 18:34:53 GMT 2025 , Edited by admin on Mon Mar 31 18:34:53 GMT 2025
PRIMARY
USAN
EF-35
Created by admin on Mon Mar 31 18:34:53 GMT 2025 , Edited by admin on Mon Mar 31 18:34:53 GMT 2025
PRIMARY
DRUG BANK
DB14974
Created by admin on Mon Mar 31 18:34:53 GMT 2025 , Edited by admin on Mon Mar 31 18:34:53 GMT 2025
PRIMARY
EPA CompTox
DTXSID801028095
Created by admin on Mon Mar 31 18:34:53 GMT 2025 , Edited by admin on Mon Mar 31 18:34:53 GMT 2025
PRIMARY
CAS
1629869-44-8
Created by admin on Mon Mar 31 18:34:53 GMT 2025 , Edited by admin on Mon Mar 31 18:34:53 GMT 2025
PRIMARY
Related Record Type Details
Structure of PIMODIVIR HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of PIMODIVIR HYDROCHLORIDE ANHYDROUS
SALT/SOLVATE -> PARENT
INFLUENZA A VIRUS WHOLE
TARGET ORGANISM->INHIBITOR
Related Record Type Details
Structure of PIMODIVIR
ACTIVE MOIETY
Originator: Vertex Pharmaceuticals; Developer: Janssen Pharmaceuticals, Vertex Pharmaceuticals; Class: Antiviral; Mechanism of Action: Viral protein inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase II for Influenza A virus infections; Most Recent Events: 01 Jun 2016 Janssen Research and Development completes a pharmacokinetics phase I trial in Healthy volunteers in USA and Belgium (PO) (NCT02652650), 01 Apr 2016 Janssen Research and Development completes a bioavailability phase I trial in Healthy volunteers in Belgium (PO) (NCT02659735), 01 Apr 2016 Janssen Research & Development completes a phase I trial in Healthy volunteers in Belgium (NCT02658825)
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966